Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Melanoma 9Prostatic Neoplasms 4Neoplasms 3Uveal Melanoma 2Stomach Neoplasms 1Renal Insufficiency, Chronic 1Oligodendroglioma 1Multiple Myeloma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Glioma 1Glioblastoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Bile Duct Neoplasms 1Astrocytoma 1

Interventions

Rituximab 313Cyclophosphamide 286fludarabine phosphate 213fludarabine 140ibrutinib 121Peripheral Blood Stem Cell Transplantation 116venetoclax 108Mycophenolic Acid 102obinutuzumab 88Lenalidomide 88Bendamustine Hydrochloride 87Whole-Body Irradiation 85Filgrastim 84Tacrolimus 78Cyclosporine 78Busulfan 70Melphalan 65Radiotherapy 63Antilymphocyte Serum 61Alemtuzumab 58Etoposide 56acalabrutinib 54Methotrexate 49ofatumumab 46idelalisib 38Cytarabine 33Chlorambucil 33zanubrutinib 31sargramostim 30Specimen Handling 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Lymphocytic, Chronic, B-Cell × Protein Subunit Vaccines × Clear all
NCT02802943 2022-11-28

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

University Hospital Tuebingen

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡